Blog
The case for patient-controlled rare disease data across science, policy, and the lived experience.
Featured
RegulatoryOur FDA Comment: Plausible Mechanism Framework Draft Guidance
Cureledger’s April 22, 2026 comment to Docket FDA-2026-D-1256: natural history data standards, privacy for small populations, and data lifecycle, reuse, and custody under the PMF.
Read →This week
The Data That Saves: How Robert Guthrie Built the Infrastructure for a Cure
In 1960, a microbiologist solved two problems at once: detecting PKU and collecting the specimen from every newborn, everywhere, without requiring infrastructure most families would never access. We named our platform after him.
Read →Ultra-rareEthan Perlstein and the other n-of-1
The n-of-1 conversation is dominated by ASOs and AAV gene therapies that produce custom-built molecules. Perlstein's argument for the past decade is that small-molecule drug repurposing in model organisms can help many ultra-rare families faster and cheaper, when the biology cooperates.
Read →Newborn screeningWhat is newborn screening, in plain words
Heel-prick blood, a federal panel, and what state-by-state coverage actually looks like.
Read →Search articles
Browse by tag
Clear ×By stream
Read all12 of 106 · Stream: Cureledger mission
- Apr 22, 2026Our FDA Comment: Plausible Mechanism Framework Draft Guidance
- Apr 22, 2026Our Founder
- Apr 22, 2026The Data That Saves: How Robert Guthrie Built the Infrastructure for a Cure
- Apr 22, 2026What "Best Case" Looks Like in Rare Disease
- Apr 22, 2026From N-of-1 to Engine of Cures
- Apr 22, 2026Small Datasets Are Not Small When They Are Dense
- Apr 22, 2026You Are Not a Subject
- Apr 22, 2026The FDA Is Ready. The Infrastructure Is Not.
- Apr 22, 2026Cures, Not Management
- Apr 22, 2026We Are Not 23andMe
- Apr 22, 2026The Regulatory Landscape Is Finally Ready
- Apr 22, 2026Henrietta Lacks at Scale